1. Introduction
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholders
2. Research Methodology
2.1. Research Design
2.2. Research Process
2.3. Data Validation
3. Executive Summary
3.1. Key Findings
3.2. Analyst View
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Supplier
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Immunoassay Market By Type
5.1. Introduction
5.2. Radioimmunoassay (RIA)
5.3. Enzyme Immunoassay or Enzyme-linked Immunosorbent Assays (ELISA)
5.4. Counting Immunoassay (CIA)
5.5. Fluoroimmunoassay (FIA)
5.6. Chemiluminescence Immunoassay (CLIA)
6. Immunoassay Market By Therapeutic Area
6.1. Introduction
6.2. Infectious Diseases
6.3. Bone Metabolism
6.4. Immunology
6.5. Neurobiology
6.6. Others
7. Immunoassay Market By End-User
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Diagnostics
7.4. Pharmaceutical & Biotechnology Companies
7.5. Research & Academic Laboratories
8. Immunoassay Market By Geography
8.1. Introduction
8.2. North America
8.2.1. By Type
8.2.2. By Therapeutic Area
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. United States
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Type
8.3.2. By Therapeutic Area
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Type
8.4.2. By Therapeutic Area
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. UK
8.4.4.2. France
8.4.4.3. Germany
8.4.4.4. Italy
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Type
8.5.2. By Therapeutic Area
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. UAE
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Type
8.6.2. By Therapeutic Area
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. Japan
8.6.4.2. China
8.6.4.3. India
8.6.4.4. Thailand
8.6.4.5. Taiwan
8.6.4.6. Indonesia
8.6.4.7. Others
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. Company Profiles
10.1. Fujirebio
10.2. QuidelOrtho Corporation
10.3. Roche Diagnostics
10.4. IDS Immunodiagnostic Systems
10.5. Arbor Assays
10.6. Beckman Coulter Inc.
10.7. ImmunoReagents Inc.
10.8. Abbott
10.9. Mercodia AB
10.10. Thermo Fisher Scientific
10.11. Siemens Healthineers
10.12. Bio-Rad Laboratories
10.13. BioServUK Ltd.